Tagungsprogramm
(Scientific Program)

XXXII. Jahrestagung der Kind-Philipp-Stiftung
für Leukämieforschung
in Wilsede
vom 5. – 7. Juni 2019

UKH Universitätsklinikum Halle (Saale)

Medizinische Fakultät der Martin-Luther-Universität Halle-Wittenberg

MHH Medizinische Hochschule Hannover

Princes MÁXIMA centrum voor kinderoncologie

GOETHE UNIVERSITÄT FRANKFURT AM MAIN

Ausrichter (organized by):

Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Halle; Institut für Pharmazeutische Biologie, Goethe Universität Frankfurt am Main; Pädiatrische Hämatologie und Onkologie, Medizinische Hochschule Hannover; Princess Maxima Center for Pediatric Oncology, Utrecht

Supported by:

- Stifterverband für die deutsche Wissenschaft, DSZ Deutsches Stiftungszentrum, Kind-Philipp-Stiftung
- Verein für krebskranke Kinder Hannover e.V.
- Roche Pharma AG, Grenzach-Wyhlen
- Förderverein für krebskranke Kinder e.V. Freiburg
- SERVIER Deutschland GmbH, München
- Eurocept International B.V., Ankeveen
- Hilfe für krebskranke Kinder Frankfurt e.V.
- Abteilung für Kinder- und Jugendmedizin des Universitätsklinikums Ulm
- Fördergemeinschaft Kinderkrebs-Zentrum Hamburg e.V.

PROGRAM AT A GLANCE



WEDNESDAY, June 5, 2019

16:00 - 17:30 h	**Welcome and registration**
17:30 – 17:45 h	**Opening of the meeting – Rolf Marschalek**
17:45 – 18:30 h	**(1) Opening Lecture** *Chair: Jan-Henning Klusmann* **Prof. Dr. Thomas Mercher** **Ontogeny-dependent susceptibility to fusion oncogenes controls pediatric myeloid leukemia** Institut Gustave Roussy; *Villejuif*
18:30 – 19:45 h	**(2) Omics studies** *Chair: Thomas Sternsdorf* 2.a Mutational and transcriptomic landscapes in hematopoietic cells of Fanconi anemia patients. Mittapalli, VR; *Freiburg* 2.b Mapping the single cell transcriptome reveals the cellular composition of ATRT subgroups Buellesbach, A; *Heidelberg* 2.c Giant cell glioblastoma does not represent a distinct entity but stratifies into different genetically defined entities Wiedey, A; *Bonn* 2.d WNT Medulloblastoma: More than just β-Catenin Mutations – Rare Genetic Features in the Focus Goschzik, T; *Bonn* 2.e Epigenetics profiling for minimal residual disease in paediatric acute myeloid leukaemia Al Ameri, M; *London*
19:45	**Dinner**

THURSDAY, June 6, 2019

09:00 - 10:45 h — **(3) Molecular mechanisms of disease I**

Chair: Owen Williams

3.a Splicing factors of the SF3b complex PHF5A and SF3B1 regulate the DNA damage response in ALL
Moorthy, S; *Newcastle upon Tyne*

3.b Inactivation of Nsd1 impairs terminal erythroid maturation and induces erythroleukemia
Tauchmann, S; *Basel*

3.c TRIM28 haploinsufficiency predisposes to Wilms tumor
Metzler, M*; Erlangen*

3.d CRISPR-mediated genome editing of t(4;11) in human prenatal and perinatal hematopoietic stem/progenitor cells
Torres-Ruiz, R*; Barcelona*

3.e Therapeutic application of the tumour suppressive miR-193b in acute myeloid leukaemia
Issa, H; *Halle*

3.f Genome-wide CRISPR screen in patient derived cells reveals the mechanism of ALL chemoresistance
Szoltysek, K; *Newcastle upon Tyne*

3.g CRISPRi screen to identify functional long noncoding RNAs in pediatric acute myeloid leukemia
Ng, M; *Halle*

10:45 - 11:00 h — *Coffee break*

11:00 - 12:45 h — **(4) Drugs I**

Chair: Torsten Pietsch

4.a Tumour Necrosis Factor receptor (TNFR)-signalling dependent killing in T-cell acute lymphoblastic leukaemia (T-ALL)
Krippner-Heidenreich, A; *Utrecht*

4.b iPSC Model of Stepwise Leukemia Development in Congenital Neutropenia Reveals BAALC as a Key Mediator of Leukemogenesis
Dannenmann, B; *Tübingen*

4.c Targeting c-MYB in Acute Leukaemia through Drug Repositioning
Clesham KJ; *London*

4.d Functional analysis of class I HDAC inhibition in group 3 medulloblastoma to identify synergistic drug combinations
Vollmer, J; *Heidelberg*

4.e Screening assay to identify potential Taspase1 inhibitors
Luciano, V; *Frankfurt*

4.f Analyzing the therapeutic efficacy of navitoclax and MCL-1 inhibitors in juvenile myelomonyctic leukemia
Wu, Y; *Freiburg*

4.g Establishment of new therapeutic options for the treatment of Myeloid Leukemia in Down syndrome (ML-DS)
Samulowski, D; *Halle*

12:45 - 14:15 h — *Lunch (Wilsede, Heidemuseum)*

14:15 – 15:45 h	(5) Diagnostics and Biomarkers *Chair: Roland Kappler* 5.a Masked hypodiploidy against uniparental disomies in hyperdiploid ALL: Observations from the diagnostics perspective Schieck, M*; Hannover* 5.b Large amplicon droplet digital PCR for DNA-based monitoring of pediatric chronic myeloid leukemia (CML) Krumbholz, M*; Erlangen* 5.c Stratification and prognosis of IGH-DUX4 positive acute lymphoblastic leukemia in children Müller, J*; Kiel* 5.d Multiplex droplet digital PCR-based targeted enrichment NGS for identification of tumor markers in Ewing sarcoma (EwS) Eiblwieser, J*; Erlangen* 5.e Machine learning algorithms for the automated classification of pediatric anemia Zierk, J*; Erlangen* 5.f Identification of the genetic mechanisms linked to the occurrence of H3.3K27M mutation in pediatric diffuse intrinsic pontine gliomas Kubiak, K*; Göttingen*
15:45 – 16:15 h	*Coffee Break*
16:15 – 17:45 h	(6) Molecular mechanisms of disease II *Chair: Deepali Pal* 6.a Deciphering the interactive network of the DLK1-DIO3 locus in hematopoiesis and pediatric acute megakaryoblastic leukemia Verboon LJ*; Halle* 6.b Identification of GATA1s interaction partners in Down syndrome-associated myeloid leukemia Bräuer-Hartmann, D*; Halle* 6.c Isolation and characterization of tumor-derived exosomes from a patient-derived xenograft mouse model of acute leukemia Bartholomé, R*; München* 6.d Interrogating the role of chromatin regulator BRD4 in the DNA damage response in medulloblastoma Vu-Han, T-L*; Hamburg* 6.e Analyzing the effects of oncogenic SHP2 on apoptosis signaling during malignant transformation Koleci, N*; Freiburg* 6.f Chromosome structure and mitotic defects are major pathogenic mechanisms in hyperdiploid childhood B-ALL. Molina, O*; Barcelona*
18:15 - 19:00 h	(7) Invited Lecture: Senior-Prof. em. Dr. Meinolf Suttorp *Chair: Karl Welte* Do you know a chimera? Pediatric Hematology and Oncology Medical Faculty, Technical University Dresden; *Dresden*
19:00 h	*Barbecue*
Starting later	*Evening with the famous Mac-Guitar*

FRIDAY, June 7, 2019

09:00 - 10:30 h — **(8) Immunotherapy**

Chair: Olaf Heidenreich

8.a Development of a novel central nervous system (CNS)-targeted CD19-antibody (AB) in acute lymphoblastic leukemia (ALL)
Winterberg, D; *Kiel*

8.b CD19 and CD22-directed bispecific CAR for B-cell acute lymphoblastic leukemia
Zanetti, SR; *Barcelona*

8.c Low regulatory T-cells are associated with improved survival of neuroblastoma patients treated with anti-GD2 antibodies
Troschke-Meurer. S; *Greifswald*

8.d CRISPR/Cas9 Gene-modification Platform of ELANE Mutations in iPSCs and HSPCs of Severe Congenital Neutropenia Patients
Nasri, M*; Tübingen*

8.e Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies
Heymann, J; *Kiel*

8.f Blockade of suppressive myeloid cells is effective against neuroblastoma
von Lojewski, L; *Tübingen*

10:30 – 10:45 h — *Coffee break*

10:45 - 12:30 h — **(9) Molecular mechanisms of disease III**

Chair: Jasper de Boer

9.a Too little is too much: Leukemogenesis in the Gata2 syndrome
Weiss, JM*; Freiburg*

9.b Using acute promyelocytic leukemia to study the H3.3 histone chaperone system and its role in pediatric malignancies
Cui, W; *Hamburg*

9.c Functional characterization of RUNX1 variants in the context of FPDMM
Decker, M; *Hannover*

9.d FOS and FOSB are linked with CNS-infiltration and inferior prognosis in childhood T-cell acute lymphoblastic leukemia
Spory, L; *Kiel*

9.e Deciphering role of lncRNAs in pediatric AML
Bhayadia, R*; Halle*

9.f Genomic characterisation of lineage switched MLL-rearranged leukemias
Tirtakusuma, R; *Newcastle upon Tyne*

9.g Downstream effect of CSF3R and RUNX1 mutations that underlie leukemic transformations in congenital neutropenia (CN)
Ritter, MU; *Tübingen*

12:30 - 13:45 h — *Lunch (Wilsede, Heidemuseum)*

13:45 - 15:00 h	(10) Molecular mechanisms of disease IV *Chair: Markus Metzler* 10.a Identification of a new splice variant of the human transcription factor ONECUT2 Lein, P*; Halle* 10.b NAMPT-mediated LMO2 deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis Morishima, T; *Tübingen* 10.c GADD45b plays an essential role in the G-CSF triggered granulocytic differentiation of human hematopoietic cells Mir, P; *Tübingen* 10.d Tripartite motif-containing 71 (TRIM71) is a major factor of oncogenic activity in human hepatoblastoma Jiang, T; *München* 10.e Cooperativity between miR-125b and Gata1s in the pathogenesis of Down syndrome-associated myeloid leukemia Alejo-Valle, O; *Halle*
15:00 - 15:15 h	*Coffee break*
15:15 - 16:45 h	(11) Drugs II *Chair: Julia Skokowa* 11.a Investigating HDACi and dnTaspase1 for the treatment of (4;11) leukemic cells Wilhelm, A; *Frankfurt* 11.b Dasatinib and dexamethasone offer a novel therapeutic strategy for T-cell acute lymphoblastic leukaemia Yuzhe, S; *Newcastle upon Tyne* 11.c Drug repositioning in infant leukaemia Looi-Somoye, R; *London* 11.d Synthetic lethality of Wnt pathway activation and asparaginase in drug-resistant acute leukemias Hinze, L; *Hannover* 11.e A human BM-iPSC-derived oncogenic niche identifies CDH2 as therapeutic niche target in leukemia Pal, D; *Newcastle upon Tyne* 11.f Inhibition of the polycomb repressive complex 1 (PRC1) as a therapeutic option in childhood liver tumors Bentrop, M; *München*
16:45 - 17:00 h	Wilsede Award and subsequent closure of the meeting – Martin Stanulla
16:50 - 17:15 h	Farewell at the Emhoff
17:15 h	Departure of the coaches to Undeloh
18:00 h	Bus transfer to Hamburg Dammtor railway station